A Phase 1, Open-label, Non-randomized, 2-period, Fixed Sequence Study To Investigate The Absorption, Metabolism And Excretion Of [14c-pf-04965842] And To Assess The Absolute Bioavailability And Fraction Absorbed Of Pf-04965842 In Healthy Male Subjects Using A 14c-microtracer Approach
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Abrocitinib (Primary) ; Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Oct 2017 Status changed from recruiting to completed.
- 05 Sep 2017 Planned End Date changed from 15 Sep 2017 to 1 Sep 2017.
- 05 Sep 2017 Planned primary completion date changed from 15 Sep 2017 to 1 Sep 2017.